Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-A8-A0A7-01A-11R-A00Z-07

— · D

bb494b02-aa3c-546a-bcdb-347d338d7b4f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D
overall_survival_months
1
os_event
false

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.650
  • INTERFERON_GAMMA_RESPONSE+0.640
  • INTERFERON_ALPHA_RESPONSE+0.600
  • IL6_JAK_STAT3_SIGNALING+0.500
  • INFLAMMATORY_RESPONSE+0.480
  • COMPLEMENT+0.430
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
  • KRAS_SIGNALING_UP+0.320
  • IL2_STAT5_SIGNALING+0.300
  • PROTEIN_SECRETION+0.300

Top 10 suppressed

  • MYC_TARGETS_V2-0.510
  • WNT_BETA_CATENIN_SIGNALING-0.380
  • ESTROGEN_RESPONSE_EARLY-0.340
  • ESTROGEN_RESPONSE_LATE-0.300
  • UNFOLDED_PROTEIN_RESPONSE-0.240
  • MITOTIC_SPINDLE-0.230
  • G2M_CHECKPOINT-0.220
  • NOTCH_SIGNALING-0.220
  • E2F_TARGETS-0.170
  • MYC_TARGETS_V1-0.160

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MBCProject_5809_T1_RNA
breast-umap@18
—C0.866
2SRR8518368
breast-umap@18
—D0.866
3ERR2208891
melanoma-umap@29
——0.855
4SRR35579799
breast-umap@18
—D0.853
520100100.Her2HRpos
breast-umap@18
—D0.851
6TCGA-CQ-5325-01A-01R-1686-07
head-neck@1
——0.845
7TCGA-50-5049-01A-01R-1628-07
lung-landscapes@6
—cohortA10.839
8MBCProject_3808_T3_RNA
breast-umap@18
—A0.837
9TCGA-75-5122-01A-01R-1755-07
lung-landscapes@6
—cohortA10.834
1020110002.Her2HRneg
breast-umap@18
—D0.827

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.650Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.640Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.600Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.500Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.480Idelalisib— uncovered
COMPLEMENT0.430Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.330Inavolisib— uncovered
KRAS_SIGNALING_UP0.320Inavolisib— uncovered
IL2_STAT5_SIGNALING0.300Idelalisib— uncovered
PROTEIN_SECRETION0.300Remibrutinib— uncovered
COAGULATION0.280Binimetinib— uncovered
PI3K_AKT_MTOR_SIGNALING0.280Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.280Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.270Inavolisib— uncovered
MTORC1_SIGNALING0.260Inavolisib— uncovered
APOPTOSIS0.230Idelalisib— uncovered
PANCREAS_BETA_CELLS0.230Cobimetinib— uncovered
ANDROGEN_RESPONSE0.210Inavolisib— uncovered
KRAS_SIGNALING_DN0.210Remibrutinib— uncovered
BILE_ACID_METABOLISM0.180Inavolisib— uncovered